• Recruiting

NCT04754945: Phase 1: Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

NCT04754945: Phase 1: Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis


isatuximab

NCT04754945: Phase 1: Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis


This phase I trial studies the side effects of isatuximab and to see how well it works in treating patients with high risk immunoglobulin light chain amyloidosis (AL amyloidosis). Isatuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.


Sponsor

Emory University


Collaborators

Sanofi

National Cancer Institute (NCI)


Information provided by (Responsible Party)

Craig Hofmeister, Emory University

 

ClinicalTrials.gov Identifier: NCT04754945

Official Title: Slow-Go Strategy for High Risk AL Amyloidosis: Isatuximab for Upfront Therapy

First Posted : February 15, 2021

Click here to see details on ClinicalTrials.gov

 

Drug: Bortezomib

Drug: Cyclophosphamide

Drug: Dexamethasone

Biological: Isatuximab

 

Isatuximab : National Cancer Institute

Isatuximab : MedlinePlus Drug Information

 

Locations

United States, Georgia

United States, California

United States, Michigan

United States, New York

United States, Texas





Posts Archive